Legislator Brief · one page · drafted to be printed and carried into a meeting
Corporate control of clinical judgement
A prohibition on lay control of clinical judgement means nothing until the levers of control are named.
Object type
Legislator Brief
Label
MODEL REGULATION
Status
OPEN FOR CRITIQUE
Jurisdiction
California
Domain
Physician independence & ownership
Baseline verified
2026-08-30
Issue
California's bar on corporate practice of medicine prohibits lay control of clinical judgement, but the levers through which control is actually exercised — productivity targets, panel size, referral steering, template design, coding pressure, staffing ratios, schedule control, termination-without-cause — are nowhere enumerated.
Why now
Practice acquisition continues, management-services agreements are now the standard structure, and enforcement has no operative definition of the conduct it prohibits.
Current law
The corporate-practice doctrine and the professional-corporation provisions prohibit lay interference with professional judgement; the Attorney General reviews certain health-facility transactions. No regulation enumerates prohibited levers.
Policy gap
A prohibition without an enumerated conduct list is unenforceable in the cases that matter, and it also fails to protect ordinary administrative services from over-reading.
KPSGILL recommendation
Implement the statute by regulation: enumerate the eight levers, expressly permit ordinary administrative services, require disclosure of the management agreement to each licensee practising under it, and make the target-setter traceable.
Who can act
Cost
Analysis, not projection. Compliance cost is disclosure and record-keeping at the management entity. Enforcement cost is one rulemaking plus complaint handling. No new programme.
Trade-offs
| Dimension | Direction | Basis |
|---|---|---|
| Physician autonomy | ↑ increase | The purpose of the doctrine, made operative. |
| Administrative complexity | ↑ increase | Disclosure and traceability are new duties. |
| Competition | ± mixed | Raises the cost of the acquisition model without prohibiting it. |
| Innovation | ~ uncertain | Care-model experimentation must document who set the target. |
| Access | ~ uncertain | If capital exits underserved markets, access falls; that risk must be monitored. |
| Litigation risk | ↑ increase | Enumerated conduct invites private claims. That is a feature and a cost. |
Who is affected
| Group | Expected impact | Why |
|---|---|---|
| Physicians | strongly favorable | A named lever list is what makes a complaint provable. |
| Patients | favorable | Referral steering and panel pressure become reviewable. |
| Hospitals | mixed | Employment models survive; explicit clinical-override terms are required. |
| Technology vendors | mixed | Template and coding-prompt design enters the enumerated list. |
| Government | favorable | Enforceable definition replaces a doctrine that cannot be applied. |
| Employers | unfavorable | Management agreements become disclosable to the clinicians bound by them. |
Policy options
Option A — status quo
Doctrine remains declaratory; enforcement remains rare and structural cases fail.
Option B — limited reform
Guidance letter listing concerns, with no rule. Non-binding and easily distinguished.
Option C — structural reform
Regulation enumerating levers, plus disclosure and traceability duties, plus a private right.
Option D — KPSGILL preferred · preferred
C without the private right in the first instrument: enumerate, disclose, trace, then measure enforcement before adding a cause of action.
How we would know it worked
- Complaints alleging enumerated levers, and disposition
- Management agreements disclosed to practising licensees
- Documented clinical overrides and any adverse action following one
- Share of acquired practices retaining physician control of panel size
The five-physician practice
Independent practices are the intended beneficiary: enumeration is what lets a physician negotiate against a management agreement instead of signing it.
Next decision point
Medical Board rulemaking calendar; any Attorney General transaction condition that could carry the enumeration first.
Model language and sources
Model statutory or regulatory language, the documentary baseline it rests on, the strongest arguments against the proposal and the KPSGILL responses to them are on the full page: Corporate control of clinical judgement: naming the levers. Related briefs are indexed at Legislator Briefs.